XFCH yields 2000000.00% · ABBV yields 3.06%● Live data
📍 XFCH pulled ahead of the other in Year 1
Combined, XFCH + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of XFCH + ABBV for your $10,000?
X-Factor Communications Holdings, Inc. provides interactive digital media network software and services in the United States. The company's flagship application include Digital Screen Control Portal, an interactive real-time digital media communications and broadcast platform that delivers single point publishing of emergency mass notifications, alerts, and rich informational content to various IP endpoint/device. Its solutions also comprise Corporate Communications Control Center, a platform for multi-media, multi-channel, and multi-dimensional internal and external corporate communications; and Marketing and Advertising Control Center for digital media network owners. In addition, the company's products consist of enterprise desktop, storefront and DMAX, multimedia player, and interactive kiosks services. Further, it offers various services consisting of creative services; a suite of professional grade digital media services, including digital media application development, live event production, content creation and management; and digital media Webcasting services that deliver compelling digital media content supporting corporate communications, marketing events, e-commerce, and information distribution services. The company serves healthcare, education, enterprise, transportation, advertising, real estate, retails, public venue, banking and financial, and other sectors. The company was formerly known as Organic Spice Imports, Inc. and changed its name to X-Factor Communications Holdings, Inc. in May 2012. The company was founded in 2005 and is based in Lyndhurst, New Jersey.
Full XFCH Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.